دورية أكاديمية
EE81 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia
العنوان: | EE81 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia |
---|---|
المؤلفون: | Dhanji, N., Van De Wetering, G., Guiot, V., Barco, V., Mejia, A., May, J.R., Garcia, J., Dyer, M. |
المصدر: | In Value in Health June 2023 26(6) Supplement:S74-S74 |
قاعدة البيانات: | ScienceDirect |
تدمد: | 10983015 |
---|---|
DOI: | 10.1016/j.jval.2023.03.385 |